Figure 4
From: Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma
NbA42 and NbA213 recognize ABCC3-expressing tumors in vivo. (a) Workflow of the experimental setup of targeting analysis of nanobodies. Nanobodies were administered at 15 mg·kg-1 intraperitoneally (i.p.) in xenografted mice with the indicated cell lines, and tumor targeting was examined using prospective ex vivo flow cytometry, 1 h after systemic injection. Image created with BioRender.com (accessed on November 19th, 2021). (b) Evaluation of the in vivo targeting of NbA42 and NbA213 in ABCC3-expressing and loss-of-function cell lines (e.g., A549 WT, and A549ABCC3KO). (c) Assessment of the potential detection of ABCC3-expressing glioblastoma tumors by NbA42 and NbA213 in vivo.
